NCT01670734View on ClinicalTrials.gov

Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Hypercholesterolemia
Interventions
DRUG

alirocumab SAR236553 (REGN727)

"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"

Trial Locations (2)

2025

Investigational Site Number 498001, Chisinau

35000

Investigational Site Number 250001, Rennes

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT01670734 - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects | Biotech Hunter | Biotech Hunter